Shattuck Labs
在场
Shattuck Labs 是一家在股票代码 STTK (US) 下上市的公司。
高管
查看带有其 22 名主要高管的组织结构图
Shattuck Labs 搜索最多的简介
- Taylor Schreiber, Chief Executive Officer and Director
- Helen Boudreau, Director
- Kate Sasser, Director
高管在Shattuck Labs变化
- Clay Siegall已作为Director加入公司 (新闻发布的2024三月5号).
- Kate Sasser已作为Director加入公司 (新闻发布的2024三月5号).
创建提醒
跟踪 Shattuck Labs 的高管变动
生物技术
Shattuck Labs 拥有 2,327 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- Chromocell的新名称是Channel Therapeutics Corporation。 (公布2024十一月22号).
- Enveda Biosciences 刚刚宣布为 130 筹款数百万美元。 (公布2024十一月22号).
- Alentis Therapeutics 刚刚宣布为 181 筹款数百万美元。 (公布2024十一月20号).
生物技术 行业的其他推荐联系人
消息
Shattuck Labs 的最新新闻稿
- Shattuck Labs Reports Third Quarter 2024 Financial Results and Recent Business Highlights
- Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway
- Shattuck Labs Announces Addition to Russell 2000® and Russell 3000® Indexes
- Shattuck Labs Announces Participation in Upcoming BTIG Virtual Biotechnology Conference
- Shattuck Labs Reports Second Quarter 2024 Financial Results and Recent Business Highlights
- Shattuck Labs to Host Investor Call and Webcast on Additional Interim Data Presented at the European Hematology Association (EHA) 2024 Congress from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk My
- Shattuck Labs Announces Orphan Drug Designation Granted by the U.S. Food and Drug Administration (FDA) for SL-172154 for the Treatment of Acute Myeloid Leukemia (AML)
- Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leuk
- Shattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients at the E
- Shattuck Labs Reports First Quarter 2024 Financial Results and Recent Business Highlights
- View more press releases Close
通过电子邮件
